These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 9469433

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.
    Romero P, Gervois N, Schneider J, Escobar P, Valmori D, Pannetier C, Steinle A, Wolfel T, Lienard D, Brichard V, van Pel A, Jotereau F, Cerottini JC.
    J Immunol; 1997 Sep 01; 159(5):2366-74. PubMed ID: 9278327
    [Abstract] [Full Text] [Related]

  • 5. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice.
    Men Y, Miconnet I, Valmori D, Rimoldi D, Cerottini JC, Romero P.
    J Immunol; 1999 Mar 15; 162(6):3566-73. PubMed ID: 10092815
    [Abstract] [Full Text] [Related]

  • 6. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
    Carrabba MG, Castelli C, Maeurer MJ, Squarcina P, Cova A, Pilla L, Renkvist N, Parmiani G, Rivoltini L.
    Cancer Res; 2003 Apr 01; 63(7):1560-7. PubMed ID: 12670905
    [Abstract] [Full Text] [Related]

  • 7. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E.
    J Immunol; 1995 Mar 01; 154(5):2257-65. PubMed ID: 7868898
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35.
    Chen Q, Jackson H, Cebon J, Gibbs P, Davis ID, Trapani JA.
    Melanoma Res; 2000 Feb 01; 10(1):16-25. PubMed ID: 10711636
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. An antigen-targeted approach to adoptive transfer therapy of cancer.
    Valmori D, Pittet MJ, Rimoldi D, Liénard D, Dunbar R, Cerundolo V, Lejeune F, Cerottini JC, Romero P.
    Cancer Res; 1999 May 01; 59(9):2167-73. PubMed ID: 10232604
    [Abstract] [Full Text] [Related]

  • 14. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
    Stevens EJ, Jacknin L, Robbins PF, Kawakami Y, el Gamil M, Rosenberg SA, Yannelli JR.
    J Immunol; 1995 Jan 15; 154(2):762-71. PubMed ID: 7814882
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development.
    Kittlesen DJ, Thompson LW, Gulden PH, Skipper JC, Colella TA, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL.
    J Immunol; 1998 Mar 01; 160(5):2099-106. PubMed ID: 9498746
    [Abstract] [Full Text] [Related]

  • 17. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.
    Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B, Economou JS.
    J Immunol; 1998 Nov 15; 161(10):5607-13. PubMed ID: 9820539
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
    Schütz A, Oertli D, Marti WR, Noppen C, Padovan E, Spagnoli GC, Heberer M, Zajac P.
    Cancer Gene Ther; 2001 Sep 15; 8(9):655-61. PubMed ID: 11593334
    [Abstract] [Full Text] [Related]

  • 19. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA.
    J Immunol; 1998 Dec 15; 161(12):6985-92. PubMed ID: 9862734
    [Abstract] [Full Text] [Related]

  • 20. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells.
    Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E.
    J Immunol; 1997 Feb 15; 158(4):1796-802. PubMed ID: 9029118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.